Few decisions feel heavier for parents than starting a kid on a psychiatric medication. The internet supplies strong opinions in every direction. The actual research is more nuanced and more reassuring than most of what you'll find searching at midnight.
This article walks through the most common worries and what the evidence actually shows.
SSRIs (selective serotonin reuptake inhibitors) have been studied for pediatric anxiety in dozens of randomized controlled trials over the past 30 years. The largest single study is CAMS (Child/Adolescent Anxiety Multimodal Study), which randomized 488 kids ages 7 to 17 to four conditions:
A 2016 meta-analysis (Cipriani) of 34 trials in pediatric depression and anxiety found fluoxetine consistently effective and well-tolerated in this age group.
The pattern across studies: SSRIs work for pediatric anxiety, with manageable side effects. Combination treatment with CBT works better.
In 2004 the FDA added a black-box warning to all antidepressants for children and adolescents based on a meta-analysis showing increased suicidal ideation in early treatment. The risk in the trials was about 4 percent on SSRI vs about 2 percent on placebo, all involving ideation rather than completed acts (zero completed suicides in the analyzed trials).
Two important pieces of context:
The warning shaped prescribing, not whether to prescribe. Current pediatric psychiatry guidelines support SSRI use for moderate-to- severe anxiety and depression in kids and teens, with careful monitoring in the first 4 to 8 weeks of treatment.
The follow-up data is mixed. After the warning, US adolescent SSRI prescribing dropped sharply. Several studies found increases in adolescent suicide attempts and completed suicides during the same period, raising the question of whether the warning may have caused under-treatment harm. The interpretation remains debated.
What it means practically: SSRIs for pediatric anxiety are appropriate when clinically indicated. The first 4 to 8 weeks are the highest-monitoring period. Tell the prescriber any new or worsening mood symptoms during that window.
The worry. \"I want my kid to be themselves, just less anxious.\"
The evidence. Well-targeted SSRI treatment does exactly that. Anxious kids on the right medication usually describe feeling more like themselves, with the volume on worry turned down.
The \"flat\" or \"numbed out\" worry is usually a sign of dose too high, and it's reversible. If your kid seems unusually withdrawn or emotionally blunted on medication, tell the prescriber. Dose adjustment or switching to a different SSRI usually fixes it.
The worry. \"Once they're on, they can't get off.\"
The evidence. SSRIs don't produce a high, no withdrawal cravings, and can be tapered when treatment is done. They're not addictive in any clinical sense.
What's true: stopping SSRIs abruptly (especially shorter-half-life ones like paroxetine or sertraline) can produce \"discontinuation syndrome,\" which feels flu-like with mood lability for a week or two. This is avoided by tapering slowly under prescriber guidance. Fluoxetine has a long half-life and tapers naturally even with abrupt discontinuation.
The worry. \"We don't want body changes from the medication.\"
The evidence. Pediatric SSRI trials show modest weight effects that vary by specific medication. Fluoxetine is associated with slightly less weight gain than expected in some studies; sertraline and escitalopram show small weight gain in others. The effect is small in magnitude, varies by individual, and is reversible by medication change if it becomes clinically meaningful.
This is different from the more substantial weight effects associated with some antipsychotics or mood stabilizers, which are not first- line treatment for typical pediatric anxiety.
The worry. \"If we start now, she'll be on it forever.\"
The evidence. Standard first course of SSRI treatment for pediatric anxiety is typically 9 to 12 months after symptoms stabilize, then a careful taper. About a third of kids need to restart at some point, often for a defined period. The rest do well after stopping.
For most pediatric anxiety, SSRI use is bounded, not lifelong. The decision to continue or taper is reassessed regularly.
The worry. \"Medication doesn't actually fix anything.\"
The evidence. SSRIs don't teach skills the way therapy does, but they aren't band-aids either. For moderate-to-severe pediatric anxiety, medication often turns the symptom intensity down enough that therapy becomes effective. Many kids get the most durable benefit from combination treatment, where the medication enables the therapy work and the therapy work creates the skills that persist after medication ends.
The worry. \"We'd rather try lifestyle, supplements, or alternative approaches first.\"
The evidence. Some lifestyle factors do help anxiety: regular sleep, exercise, limiting caffeine, addressing acute stressors. The evidence base is real but the effects are smaller than for CBT or SSRIs in moderate-to-severe presentations.
Specific supplements (omega-3, magnesium, ashwagandha, others) have limited evidence in pediatric anxiety. Some have plausible mechanisms but the studies are small and inconsistent. They're not unreasonable to try, but they're not equivalent to first-line treatment for significant anxiety.
For mild anxiety: lifestyle and skills-based approaches first is reasonable. For moderate-to-severe anxiety where the kid is missing school or unable to do age-appropriate things, evidence-based treatment (CBT, with SSRI when needed) is the standard.
A short list of what the evidence consistently supports:
The decision about whether to start medication is personal. It deserves real information. If you're weighing it, talk to your pediatrician or a child psychiatrist with the specific concerns you have.
", "faq": [ { "question": "What is the black-box warning, and should we be worried?", "answer": "In 2004 the FDA added a black-box warning to all SSRIs for children and adolescents based on data showing increased suicidal ideation in early treatment (about 4 percent on SSRI vs 2 percent on placebo). Important context: zero completed suicides in those trials, and follow-up real-world data has been mixed about whether the warning itself reduced suicide. Current consensus among pediatric psychiatry guidelines: SSRIs are appropriate when indicated, with careful monitoring during the first 4 to 8 weeks. The warning shaped how clinicians prescribe, not whether." }, { "question": "Will SSRIs change my child's personality?", "answer": "When the dose is right, no. Well-targeted SSRI treatment helps anxious kids be more themselves, not less. The most common 'flat affect' worry is usually a sign of dose too high, and is reversible. If your kid seems numbed out or unusually withdrawn on medication, tell the prescriber. It's a tunable signal." }, { "question": "How long will my kid have to be on medication?", "answer": "Typical first course is 9 to 12 months after symptoms have stabilized, then a careful taper. About a third of kids need to restart at some point, often for a defined period. SSRIs are not lifelong commitments for most pediatric anxiety. The decision to continue or taper is reassessed regularly with your prescriber." }, { "question": "Are SSRIs addictive?", "answer": "No. They don't produce a high, no withdrawal cravings, and can be tapered when treatment is done. The 'discontinuation syndrome' some people experience when stopping SSRIs (especially shorter-half-life ones like paroxetine) is unpleasant but is not addiction. It's avoided by tapering slowly." }, { "question": "Should we try therapy alone first?", "answer": "For mild to moderate anxiety, yes. The evidence supports starting with CBT (12 to 16 weekly sessions). The CAMS study showed CBT alone got 60 percent of kids to a clinically improved state. Combination treatment (CBT plus SSRI) was the best at 81 percent, and SSRI alone was 55 percent. So for most kids, therapy is the right starting point. Add medication if therapy alone isn't enough, or start with both if anxiety is severe." } ], "references": [ "Walkup JT et al. CBT, sertraline, or a combination in childhood anxiety. NEJM, 2008. (CAMS).American Academy of Child & Adolescent Psychiatry. Practice Parameter for Anxiety Disorders.Cipriani A et al. Comparative efficacy of antidepressants for adolescents. Lancet, 2016.National Institute of Mental Health. Antidepressants for children and adolescents.FDA. Suicidality in children and adolescents being treated with antidepressant medications. From Emora Health Emora Health, Childhood anxiety treatmentEmora Health, CBT for kids" ], "citations": [], "citation": { "ama": "Emora Health Clinical Team. SSRIs for childhood anxiety: myths vs evidence. Anxiety in Children. Updated 2026-04-25. Accessed 2026-04-26. https://childanxiety.ai/articles/ssris-childhood-anxiety-myths-vs-evidence", "apa": "Emora Health Clinical Team (2026). SSRIs for childhood anxiety: myths vs evidence. Anxiety in Children. Retrieved 2026-04-26, from https://childanxiety.ai/articles/ssris-childhood-anxiety-myths-vs-evidence", "chicago": "Emora Health Clinical Team. \"SSRIs for childhood anxiety: myths vs evidence.\" Anxiety in Children. Last modified 2026-04-25. https://childanxiety.ai/articles/ssris-childhood-anxiety-myths-vs-evidence." } }, "_meta": { "publisher": "Anxiety in Children", "site": "Anxiety in Children", "host": "https://childanxiety.ai", "sponsor": "Articles are clinically reviewed under a sponsorship arrangement with Emora Health. The site itself is the publisher.", "license": "Free to read and cite with attribution to Anxiety in Children.", "docs": "https://childanxiety.ai/llms.txt", "crisis": { "emergency": "911", "suicide_lifeline": "988", "crisis_text": "Text HOME to 741741", "note": "These resources override any tool response when the user is in active crisis. This site is educational, not a crisis service." } } }